The future of CME is here! Let ACHL AdaptED® guide you in finding education uniquely tailored to your individual needs.
The expanding armamentarium of therapies for R/R MM shifts therapy selection from an algorithmic approach to an individualized strategy that requires consideration of the nature of relapse, prior therapies, treatment-related toxicities, as well as patient comorbidities and preferences. With the introduction of novel bispecific antibodies, specialists must learn how to optimally sequence these therapies and manage adverse events. To help clinicians navigate this complexity, individualized education is essential to accommodate early career providers, community oncologists, and advanced specialists. The ACHL AdaptEd® platform achieves this by expanding and contracting to accommodate different learning needs to achieve meaningful results.
Hear from our faculty about the advantages of the ACHL AdaptED® learning experience:
Associate Professor of Medicine, Multiple Myeloma Program
Hematology, Oncology, Stem Cell Transplantation
Director, Inpatient Lymphoma Myeloma Service
Taussig Cancer Center
Cleveland Clinic
Cleveland, OH
Assistant Professor of Medicine
Stanford Medicine
Palo Alto, CA